Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide

on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, n = 77). Event-free survival (EFS) at 1-year as for primary endpoint was 64% and 43% in the MAC and RIC groups, respectively. Neutrophil engraftment was achieved in 98% and 94% in the MAC and RIC groups, respectively. The incidences of grades II–IV and III–IV acute graft-versus-host disease (GVHD) were 18% and 8% in the MAC group, and 14% and 5% in the RIC group, respectively. Those of all grade and moderate to severe chronic GVHD at 2-year were 36% and 20% in the MAC group, and 27% and 20% in the RIC group, respectively. Overall survival (OS), EFS, nonrelapse mortality, and relapse rate at 2-year were 68%, 54%, 10%, and 36% in the MAC group, and 44%, 35%, 20%, and 45% in the RIC group, respectively. Notably, 83% and 86% of patients who survived without relapse stopped immunosuppressant at 2-year in the MAC and RIC groups, respectively. Our results indicate that both MAC and RIC are valid options for PTCy-haploPBSCT for adults with hematological malignancies.

Original languageEnglish
Pages (from-to)432-441
Number of pages10
JournalBone Marrow Transplantation
Volume54
Issue number3
DOIs
Publication statusPublished - Mar 1 2019

Fingerprint

Peripheral Blood Stem Cell Transplantation
Graft vs Host Disease
Cyclophosphamide
Disease-Free Survival
Transplants
Recurrence
Hematologic Neoplasms
Immunosuppressive Agents
Neutrophils
Safety
Survival
Mortality
Incidence

All Science Journal Classification (ASJC) codes

  • Hematology
  • Transplantation

Cite this

Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. / on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT).

In: Bone Marrow Transplantation, Vol. 54, No. 3, 01.03.2019, p. 432-441.

Research output: Contribution to journalArticle

on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT). / Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide. In: Bone Marrow Transplantation. 2019 ; Vol. 54, No. 3. pp. 432-441.
@article{40ce460fbce3465dbd486e9c290492bf,
title = "Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide",
abstract = "We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, n = 77). Event-free survival (EFS) at 1-year as for primary endpoint was 64{\%} and 43{\%} in the MAC and RIC groups, respectively. Neutrophil engraftment was achieved in 98{\%} and 94{\%} in the MAC and RIC groups, respectively. The incidences of grades II–IV and III–IV acute graft-versus-host disease (GVHD) were 18{\%} and 8{\%} in the MAC group, and 14{\%} and 5{\%} in the RIC group, respectively. Those of all grade and moderate to severe chronic GVHD at 2-year were 36{\%} and 20{\%} in the MAC group, and 27{\%} and 20{\%} in the RIC group, respectively. Overall survival (OS), EFS, nonrelapse mortality, and relapse rate at 2-year were 68{\%}, 54{\%}, 10{\%}, and 36{\%} in the MAC group, and 44{\%}, 35{\%}, 20{\%}, and 45{\%} in the RIC group, respectively. Notably, 83{\%} and 86{\%} of patients who survived without relapse stopped immunosuppressant at 2-year in the MAC and RIC groups, respectively. Our results indicate that both MAC and RIC are valid options for PTCy-haploPBSCT for adults with hematological malignancies.",
author = "{on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)} and Junichi Sugita and Yusuke Kagaya and Toshihiro Miyamoto and Yasuhiko Shibasaki and Koji Nagafuji and Shuichi Ota and Tatsuo Furukawa and Miho Nara and Koichi Akashi and Shuichi Taniguchi and Mine Harada and Keitaro Matsuo and Takanori Teshima",
year = "2019",
month = "3",
day = "1",
doi = "10.1038/s41409-018-0279-1",
language = "English",
volume = "54",
pages = "432--441",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Myeloablative and reduced-intensity conditioning in HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide

AU - on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

AU - Sugita, Junichi

AU - Kagaya, Yusuke

AU - Miyamoto, Toshihiro

AU - Shibasaki, Yasuhiko

AU - Nagafuji, Koji

AU - Ota, Shuichi

AU - Furukawa, Tatsuo

AU - Nara, Miho

AU - Akashi, Koichi

AU - Taniguchi, Shuichi

AU - Harada, Mine

AU - Matsuo, Keitaro

AU - Teshima, Takanori

PY - 2019/3/1

Y1 - 2019/3/1

N2 - We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, n = 77). Event-free survival (EFS) at 1-year as for primary endpoint was 64% and 43% in the MAC and RIC groups, respectively. Neutrophil engraftment was achieved in 98% and 94% in the MAC and RIC groups, respectively. The incidences of grades II–IV and III–IV acute graft-versus-host disease (GVHD) were 18% and 8% in the MAC group, and 14% and 5% in the RIC group, respectively. Those of all grade and moderate to severe chronic GVHD at 2-year were 36% and 20% in the MAC group, and 27% and 20% in the RIC group, respectively. Overall survival (OS), EFS, nonrelapse mortality, and relapse rate at 2-year were 68%, 54%, 10%, and 36% in the MAC group, and 44%, 35%, 20%, and 45% in the RIC group, respectively. Notably, 83% and 86% of patients who survived without relapse stopped immunosuppressant at 2-year in the MAC and RIC groups, respectively. Our results indicate that both MAC and RIC are valid options for PTCy-haploPBSCT for adults with hematological malignancies.

AB - We conducted two parallel prospective, multicenter, phase II studies to evaluate the safety and efficacy of HLA-haploidentical peripheral blood stem cell transplantation using post-transplant cyclophosphamide (PTCy-haploPBSCT) following myeloablative conditioning (MAC, n = 50) and reduced-intensity conditioning (RIC, n = 77). Event-free survival (EFS) at 1-year as for primary endpoint was 64% and 43% in the MAC and RIC groups, respectively. Neutrophil engraftment was achieved in 98% and 94% in the MAC and RIC groups, respectively. The incidences of grades II–IV and III–IV acute graft-versus-host disease (GVHD) were 18% and 8% in the MAC group, and 14% and 5% in the RIC group, respectively. Those of all grade and moderate to severe chronic GVHD at 2-year were 36% and 20% in the MAC group, and 27% and 20% in the RIC group, respectively. Overall survival (OS), EFS, nonrelapse mortality, and relapse rate at 2-year were 68%, 54%, 10%, and 36% in the MAC group, and 44%, 35%, 20%, and 45% in the RIC group, respectively. Notably, 83% and 86% of patients who survived without relapse stopped immunosuppressant at 2-year in the MAC and RIC groups, respectively. Our results indicate that both MAC and RIC are valid options for PTCy-haploPBSCT for adults with hematological malignancies.

UR - http://www.scopus.com/inward/record.url?scp=85052517618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052517618&partnerID=8YFLogxK

U2 - 10.1038/s41409-018-0279-1

DO - 10.1038/s41409-018-0279-1

M3 - Article

VL - 54

SP - 432

EP - 441

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -